If Novartis goes global with TPM voltaren the revenue would be greater than $5-6m.
I've heard varying degrees of voltaren gel sales with the lower end being around $300m-$500m globally.
A ready made market, I would suggest they might want to transition from the old to the new, but I would also expect a more effective gel will capture a percentage of the $500-$600m oral market.
So at even 3% we're looking at $9-$10m or 5% $15m-$20m +
Add that to your market cap!
eureka report, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 4029836 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 17889240 | 5 |
View Market Depth
| Last trade - 09.28am 21/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable